From the moment it launched, through Erganeo, Kurma Partners, Idinvest Partners and Domain Therapeutics, the start-up succeeded in raising €6.3m. This financial backing supports research and development into CXCR4 biased agonists (a chemokine G protein-coupled receptor) with a view to creating oral medication for a broad range of autoimmune diseases.
Erganeo CEO Suat Topsu is delighted with the investment: “We’re thrilled to have helped turn an exceptional academic project into a promising business venture”.
“Erganeo was quick to spot the potential in our findings. Through the support it has given us since 2016, the Erganeo team has allowed us to meet investors perfectly suited to our development stage, and this very early on”, says Jean-Philippe Herbeuval, the scientific co-founder of Ermium Therapeutics.
“Being in a position to launch Ermium with such fantastic partners is a major asset and should allow us to bring the project’s full potential to fruition”, adds Joël Crouzet, the start-up’s CEO.
Read the press release
Article from Les Echos
Article from CNRS
Article from My Pharma Editions
